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Abstract: Cytapheresis is an extracorporeal separation technique widely used in medicine for elimination of specific classes 
of blood cells from circulating blood. It has been shown recently to have clinical efficacy in various disease states, such as 
leukaemia, autoimmune disorders, rheumatoid arthritis, renal allograft rejection and sickle–cell anaemia. The current study was 
undertaken to produce an affinity-binding column, based upon a macroporous monolithic cryogel with a structure of 
interconnected pores, with pore size and low flow resistance potentially suitable for use in cytapheresis. The affinity column 
was produced from poly (2-hydroxyethyl methacrylate) PHEMA cryogels synthesized by free radical polymerization at -12°C.  
This study involved assessing haemolytic potential, and functionalisation of polymer matrix with biological ligands. 
Haemolytic potential of poly (2-hydroxyethyl methacrylate) cryogel was established by measuring free haemoglobin after 
blood filtration through the column. The anti-human albumin (antibody) was chemically coupled to the epoxy derivatised 
monolithic cryogels and the binding efficiency of anti-human albumin (antibody) to the cryogel was determined. Our results 
show that approximately 100% of Red blood cells passed through the column with no evidence of haemolysis found in blood 
eluted.  It was found that ~82% of human serum albumin was retained on the monolithic IgG anti-human albumin cryogel 
matrix. The obtained results suggest that poly (2-hydroxyethyl methacrylate) monolithic cryogel is a non-haemolytic material 
(haemocompatible matrix) capable of functionalisation with antibody and thus can be an appropriate matrix for use in 
extracorporeal apheresis system. 
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1. Introduction 
Cytapheresis is aimed at separation of certain types of cells 
from blood by either centrifugation or adsorption. It has long 
been acknowledged that specific removal of pathologically 
significant cells or formed elements is an attractive 
perception. Cytapheresis has been shown recently to have 
clinical efficacy in various disease states, such as leukaemia, 
autoimmune disorders, rheumatoid arthritis, renal allograft 
rejection, and sickle–cell anaemia [1-2]. Various physicians 
have reported the efficacy of cytapheresis in inflammatory 
bowel disease such as ulcerative colitis and Crohn’s disease 
[3-8]. The efficacy of LDL-apheresis in homozygous familial 
hypercholesterolemia and hyperlipidemia has been reported 
[9, 10]. 
There are mainly three methods of extracorporeal 
leukocyte removal therapy in use in the clinical field. These 
are the centrifugal method, filtration and the adsorptive 
method using fibre or beads. Leukocytapheresis using the 
leukocyte filter Cellsorba [11] and granulocytapheresis using 
the Adacolumn [12] have been proved to have reduced 
leukocyte load in patients with rheumatoid arthritis and 
inflammatory bowel disease, but still has major limitations of 
specificity and selectivity [13]. 
The adsorptive method with beads has been used in LDL-
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apheresis with direct adsorption of lipoprotein and this has 
been proved to reduce cholesterol level in patients with 
severe dyslipidaemic and homozygous familial 
hypercholesterolaemia, but still has limitations due to side 
effects such as activation of bradykinin [14, 15]. 
Despite its excellent potential, apheresis has not yet 
received wide clinical applications for a number of reasons. 
An ideal extracorporeal cell-specific filter device should have 
combined characteristics, such as low flow resistance, high 
mechanical and chemical stability, ease of functionalisation, 
large interconnected pores which can allow unrestricted cell 
passage, a large material surface area and control of pore size 
during manufacture [16]. Current filter devices and other 
apheresis techniques do not meet all, or many of these 
requirements. It is desirable to have a monolithic column for 
therapeutic cytapheresis, with continuous on-line cell 
separation. Use of monolithic columns for chromatographic 
separations has already been suggested [17] but so far they 
have not been used for cell separations due to failure in effort 
to achieve an appropriate pore structure.  
These problems can be overcome by employing 
macroporous monolithic cryogels prepared using 
cryopolymerisation technology. Cryogels have been shown to 
have unique properties, most importantly mechanical, 
chemical and osmotic stability [18], and interconnected 
macro or supermacropores capable of allowing passage and 
separation of whole blood cells in a chromatographic regime 
[19, 20]. They have also shown shape memory as they can be 
repeatedly dried and re-swollen in the solvent acquiring the 
same shape in which they were synthesised [21, 22].  
The problem of the non-selective nature of current filter 
devices and apheresis technique has been addressed in the 
use of monolithic cryogel for chromatographic separation by 
the functionalisation of the filter support and attachment of a 
biological ligand, such as an antibody against target antigen 
or protein A (an avid ligand for IgG antibody). A 
recognisable application has been the use of anti-CD4 
antibody to remove CD4+ T-lymphocytes [23] or the more 
widely applicable functionalisation of filter support with 
protein A to capture antibody-coated cells [24]. The removal 
of anthrax toxin protective antigen with supermacroporous 
cryogel adsorbents with immobilized Protein A has been 
reported recently [25]. This allows a more targeted means of 
cell isolation, and provides a flexible technological platform 
that could be applied to a wide range of diseases in clinical 
applications.  
Overall, the technology looks promising and one hopes to 
develop cryogel bio-specific filter device to be used in 
extracorporeal medical devices that will be available 
commercially.  This however, provides the possibility that 
cryogels can be explored for clinical applications requiring 
haemocompatibility. 
Multiple factors can induce haemolysis, such as shear 
stress, RBC interaction with leachable, chemicals and 
electrical forces [26]. The most common method to 
determine the haemocompatibility properties of biomaterials 
used for blood filter is haemolysis testing. The release of 
intracellular haemoglobin (haemolysis) can be caused by Red 
blood cells (RBC) interaction with biomaterials. The 
haemolysis test has been used for decades to identify the 
biocompatibility properties of biomaterials [27-30].  
The objective of this study is to help provide 
understanding of the haemolytic potential of poly (2-
hydroxyethyl methacrylate), PHEMA monolithic cryogel, 
and further confirm that the availability of binding structure 
such as antibodies can recognize the surface of the proteins 
or cells aggregates, thus a general binding and separation 
system can be established. Considering the fact that the 
development of improved haemocompatible biomaterials is 
one of the most important challenges in material science, this 
paper demonstrated for the first time that PHEMA monolithic 
cryogel is a non-haemolytic material by passing whole blood 
through the column by mean of evaluating the free 
haemoglobin, and amount of red blood cells eluted with the 
use of Sysmex cell counter and Blakney and Dinewoodie 
(1975) method. The in-vitro studies on the 
haemocompatibility of the material produced in this paper 
reported that ~100% (4.77 x 106 cells/µL) of Red blood cells 
was eluted after passing whole blood through the monolithic 
cryogel column and that no haemolysis was observed. 
According to the international organization for 
standardization (ISO) developed guidance on testing medical 
materials that have contact with circulating blood (ISO 
10933-4), a haemocompatible material must not interact with 
any blood components.  
There is no reported study of immobilisation of anti-
human albumin (antibody) onto a monolithic cryogel via 
covalent immobilisation with extended linker groups. In this 
paper, we report for the first time the covalent immobilisation 
of anti-human albumin on macroporous cryogel columns 
having epoxy functionalities, synthesised by cryogelation. 
Affinity binding of human albumin onto coupled anti-human 
albumin on the surface of the cryogel matrix further confirms 
that if the binding structure in the form of antibodies is 
available that recognises the surface of the proteins or cells 
aggregates, a general binding and separation system can be 
established for antibody binding cryogel, affinity matrices. 
These results provide support for the use of macroporous 
monolithic cryogel in an extracorporeal apheresis medical 
device. 
2. Materials and Methods 
2.1. Materials 
2-hydroxyethyl methacrylate, (HEMA 98%, stabilised), 
allyl glycidyl ether (AGE 99%), and N, N’-methylene- 
bisacrylamide, (MBAAm 96%) were purchased from Acros 
Organics UK. N, N, N’, N’–tetramethylethylenediamine 
electrophoresis grade (TEMED 97% Fisher Bio reagents) and 
ammonium persulfate (APS) were purchased from Fisher 
Scientific UK. Fresh blood from healthy donor, 3.8% sodium 
citrate vacutainer from BD vacutainer Systems, (Franklin 
Lakes, NY, USA), bicinchoninic acid (BCA) protein assay 
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reagent, copper (II) sulphate solution, anti-human albumin 
IgG 034K4816 (anti-HSA IgG) from sheep serum and human 
serum albumin (HSA) were purchased from Sigma (St Louis 
USA), ethylenediamine from Aldrich, sodium borohydride 
from Fluka. Buffers prepared from sodium phosphate 
(monobasic and dibasic) and sodium carbonate (monobasic 
and dibasic) from Sigma. UV/Vis spectrophotometer from 
Pharmacia Biotech, Sysmex KX-21N cell counter (Sysmex 
Co., Mundelein, IL, USA) and SP syringe pump connected to 
pressure box and pressure monitor system were used. 
2.2. Cryogel Synthesis 
Epoxy containing PHEMA cryogel was produced from 
monomers of 2-hydroxyethyl methacrylate (HEMA 5.28 mL) 
and allyl glycidyl ether (AGE 1.08 mL), N, N’- 
methylenebisacrylamide (MBAAm 1.342 g) was used as a 
cross linker. These were dissolved in 92.2mL of deionized 
water (final concentration of monomers 8 % w/v), monomers 
ratio to MBAAm 6:1. The resulting solutions were degassed 
for about 20 minutes by using N2 gas or water pipe vacuum. 
Free radical polymerization was initiated by N, N, N, N-
tetramethylethylenediamine (TEMED) and ammonium 
persulphate (APS) pair (1.2 w/w % TEMED and 1.2 w/w % 
APS of the total weight of monomers and MBAAm). The 
mixture was then cooled under ice bath for about 30 minutes. 
APS was added to the solution for the onset of reaction. The 
solution (4 mL) was aliquoted into glass columns, and frozen 
at -12°C for 18 hours in a cryobath. The cryogels were 
allowed to thaw at room temperature while still in the glass 
columns before being washed with water; the gel matrix was 
stored at 4°C till further use.  
2.3. Blocking of the Epoxy Reactive Group 
The epoxy PHEMA cryogel column was washed with 0.1 
M sodium carbonate buffer, pH 9.0 at flow rate 0.5 mL/min 
for 4 hours. Then 50 mL 0.1 M ethanolamine pH 9.0 in 0.1M 
sodium carbonate buffer were pumped in a recycling mode 
for 4 hours. Finally, the column was washed with 50 mL of 
0.1 M sodium carbonate buffer at a flow rate 1 mL/min to 
remove all non-reacted ethanolamine, and then stored at 4°C 
until further use.  
2.4. Blood Collection 
Venous blood was collected by clean venepuncture into 
vacuum tubes containing anti-coagulant (sodium citrate) and 
was used within 24 hours. The volunteers four in number, 
were healthy and had not taken aspirin or non-steroidal anti-
inflammatory drugs within the last 24 hours.  The blood 
collection was done after approval by the Ethics Committee 
of University of Brighton (Approval number: PABSREC 
APPLICATION 0902). 
2.5. Blood Cell Count 
The whole blood was counted with Sysmex KX-21N, an 
automated multiparameter blood cell counter for in-vitro 
diagnostic use in clinical laboratories. This system processes 
approximately 60 samples an hour and displays on the liquid 
crystal display screen the particle distribution curves of white 
blood cells (WBC), red blood cells (RBC) and platelets, 
along with data of 19 parameters. WBC and RBC use direct 
current detection method. The haemoglobin detector block 
measures haemoglobin concentration using the non–cyanide 
haemoglobin analysis method. Non-cyanide haemoglobin 
analysis method applies the advantages of both 
cyanmethaemoglobin and oxyhaemoglobin methods. Non-
cyanide haemoglobin analysis method rapidly converts blood 
haemoglobin as the oxyhaemoglobin method and contains no 
poisonous substance, making it suitable for automated 
method. This method is capable of analysing 
methaemoglobin, hence it can accurately analyse blood, 
which contain methaemoglobin.  
The cryogel column was washed with approximately 50 
mL of 0.9% NaCl solution at a flow rate of 1 mL/min with 
the use of SP 200 syringe pump, then approximately 15 mL 
of blood were passed through the pump at a speed of 1 
mL/min, as shown in Fig: 2.1 and the fractions of 
approximately 1 mL were collected into an eppendorf tube 
for ~ 12minutes. The fractions in each tube were then 
evaluated for the cell numbers.  
Red blood cell (RBC) count in blood was performed using 
a Sysmex cell counter and the initial value was observed 
before passing blood through the column. The experiment 
was repeated four different times and Red blood cell count 
were evaluated from the blood eluted after passage through 
the cryogel column.  Blood was pumped through the column 
at a flow rate of 1 mL/min up until 12minutes. The first 5 mL 
eluted were discharged to make sure any dilution of blood 
samples with 0.9% NaCl used to wash the column did not 
occur. Therefore, blood samples collected after 5 mL 
contained whole blood only as shown in Fig: 2.2. 
 
Figure 2.1. SP 200 syringe pump ready to pump blood through the cryogel 
column connected to the pressure box and the pressure monitor system. The 
metal clamps are used to close the tubes leading to the pressure box while 
loading blood sample.  
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Figure 2.2. Flow of blood passing through the cryogel matrix at different 
times. No side flow leakage within the column was observed. 
2.6. Plasma Haemoglobin Determination 
Haemolytic potential of PHEMA cryogels has been 
evaluated by the haemolysis test. The haemolysis test is a 
qualitative characteristic that measures the free haemoglobin 
present in supernatant of the test sample; this measurement 
can be done photo-metrically. 
To determine the effect of monolithic PHEMA cryogels on 
blood cells after transiting through the column, the following 
steps were taken.  
i) The number of various blood cells in whole blood before 
passage through the column was estimated. ii) The pressure 
difference through the column during whole blood passage 
was measured. iii) Estimation of blood cells number eluted 
after transition through the column was done. iv) Evaluation 
of Red blood cells lysis was determined. 
Freshly collected whole blood was passed through 8% 
PHEMA cryogel at a flow rate of   1 mL/min with SP200 
syringe pump connected to a pressure monitor device as 
shown in Fig. 2.1. Approximately 12 mL of blood was passed 
through the cryogel column and 1 mL fractions were 
collected into eppendorf and analysed for haemolysis. This 
experiment was repeated four different times. 
1 mL aliquots of blood from test samples were centrifuged 
at 1000 g for 10 minutes and the plasma was placed in 
another eppendorf tube. The absorbance of the plasma (300 
µL) was read and recorded at 3 wavelengths (562, 578 and 
598 nm). The plasma haemoglobin concentration was 
calculated according to [30]. The total haemoglobin content 
(volume (gram) of haemoglobin in dL of whole blood) was 
measured with the Sysmex cell counter.  Control samples 
(negative control 0.9% NaCl in a 1:1 dilution with blood 
sample and positive control 1:1 dilution with deionized 
water) were incubated for 1 hour at room temperature. At the 
end of the incubation period, the samples were treated as 
described with test sample. Final plasma haemolysis was 
calculated as haemolytic index, this experiment was repeated 
four times for result comparison. 
Calculation used for free plasma haemoglobin: 
Free plasma Haemoglobin (mg/dL) = (A578 X 155) – (A562 
X 86) – (A598 X 69) =  
To convert to Free plasma Haemoglobin (g/L) = Free 
plasma Haemoglobin /    
Evaluation of results: 
The haemolytic index is calculated according to Equation 
2.1.      !!"#$  %&'()!*   !!"#$ +!$+ $* %&'(  , 100      Equation 2.1 
2.7. Coupling of IgG Ligand onto Monolithic Epoxy 
PHEMA Cryogels 
The epoxy PHEMA monolithic cryogels were treated as 
follows. The 4mL cryogel column was connected to a pump 
and washed with ~ 50 mL deionized water at a flow rate of 
1mL/min, and then with 0.1 M sodium carbonate buffer pH 
9.2 (30 mL). Ethylenediamine (30 mL of 0.5 M 
ethylenediamine in 0.1 M sodium carbonate buffer pH 9.2) 
was applied to the column at flow rate of 1mL/min in recycle 
mode for 4hours. After washing with water until the pH was 
close to neutral, the column was washed with 0.1 M sodium 
phosphate buffer pH 7.2. A solution of 5% v/v, 
glutaraldehyde (50mL) in 0.1 M sodium phosphate buffer pH 
7.2, was applied to the column at flow rate of 1mL/min in 
recycle mode for 5hours. 
The derivatised cryogel matrices with functional aldehyde 
group were washed with 0.1 M sodium phosphate pH 7.2 
buffer ~50mL. The derivatised matrix with functional 
aldehyde groups was used for coupling of IgG. The IgG 
solution (10.3mg/mL of IgG dissolved in 20 mL of 0.1 M 
sodium phosphate buffer pH 7.2), was recycled through the 
column at flow rate 1mL/min at 4°C for 24 hours. The 
monoliths were then washed with sodium phosphate buffer 
pH 7.2 ~50mL. Finally the freshly prepared NaBH4 solution, 
0.05M sodium borohydride solution, in 0.1M sodium 
carbonate buffer, pH 9.2 was applied to the cryogel column at 
a flow rate of 1mL/min for 3 hours in recycle mode to reduce 
Schiff’s base formed between the protein (IgG) and the 
aldehyde-containing matrix. The monoliths were then washed 
with 0.1M sodium phosphate buffer pH 7.2 ~50mL and 
stored at 4°C till further use. 
 
Figure 2.3. Schematic representation illustrating pathways to activate epoxy 
containing cryogel for antibody attachment. 
2.8. Affinity Binding of Human Serum Albumin to Cryogel 
Matrix with Immobilised Anti- human Albumin (Anti-
HSA IgG) Ligands 
In order to evaluate the application of the separation 
strategy on another cell system, IgG cryogel matrix was used 
O
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Matrix Matrix 
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NaCNBH3 
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for capturing human serum albumin. Cryogel monoliths with 
immobilised anti-HSA IgG were produced as described in 
section 2.7. The HSA solution (prepared by dissolving 37mg 
of human serum albumin in 45 mL of 0.1 M sodium 
phosphate buffers, pH 7.2) was recycled through the column 
at flow rate 1mL/min at 4°C for 24 hours. The monoliths 
were then washed with 0.1 M sodium phosphate buffers, pH 
7.2 ~50mL each. These monoliths were then stored at 4°C till 
further use in the wet state. 
2.9. Determination of Protein Content by Bicinchoninic 
Acid (BCA) Method 
The amount of protein content immobilised on epoxy 
PHEMA monolithic cryogel matrix was determined by the 
bicinchoninic acid method [31]. The BCA stock solution was 
freshly prepared by mixing bicinchoninic acid solution and 
copper (II) sulphate at a ratio of 50:1 (v/v) respectively. The 
cryogel matrix was dried in the oven at 60°C overnight, and 
was then ground finely into powder. A suitable amount of 
dried IgG cryogel were suspended in 1 mL of the BCA 
solution and the mixture was incubated at 37°C with 
thorough shaking for 30 minutes. The absorbance was 
measured at 562 nm both with and without centrifuging the 
samples. As the appropriate controls, epoxy PHEMA cryogel 
were used. For the standard curve, samples of diluted anti-
human albumin solutions (IgG) were prepared by serial 
dilution of 4.675 mg/mL IgG solution in 0.1 M sodium 
phosphate buffers, pH 7.2 to yield a calibration curve 
between 0.07 mg/mL to 1 mg/mL. As a blank, PBS solution 
was used. The analysis of each sample was done in triplicate. 
UV absorbance was read against the blanks at 562 nm and an 
average value was recorded.  
Thereafter, the amount of protein in the unknown sample 
was obtained from the standard curve. The protein based 
immobilisation yield was calculated as the percentage of the 
protein content of the cryogel immobilised with IgG to the 
respective amount of protein used for immobilisation. 
3. Results 
3.1. Flow of Whole Blood through Cryogel Column 
 
Figure 3.1. ∆Pressure against flow rate as pump passes blood through 8% 
PHEMA cryogel column at a speed of 1 mL/min. 
Whole blood was passed through the column at a flow rate 
of 1 mL/min and at approximately 6 mL or 6 minutes the 
column was filled with blood as shown in Fig 2.2, the 
maximum pressure of approximately 81mmHg was observed 
as shown in Fig.3.2. The gel matrix did not compress or 
reduce in size, which indicates that the cryogel matrix 
comprises macroporous interconnected pores, which allow 
the passage of various cells in the blood at a pressure of 
approximately 81mmHg at 1 mL/min flow rate. These data 
suggest the column is mechanically stable and comprises 
macroporous interconnected pores. 
3.2. Blood Cell Count by Sysmex Cell Counter  
About 95% of the red blood cells were eluted at 6 minutes 
and after 9 minutes full recovery of RBC was observed 
 
Figure 3.2. RBC counts after blood flow through the 8% PHEMA cryogel 
column. 
No haemolysis was observed in any samples eluted from 
the four 8% PHEMA cryogel columns as shown in Table 3.2 
and 3.3, using the conversion haemolytic index in Table, 3.1. 
[32]. The results from Sysmex cell counter correlate with 
data from Blankey and Dinewoodie spectra method. 
Table 3.1. Conversion table of haemolytic index. 
Haemolytic index (%) Haemolytic grade 
0-2 Non haemolytic 
2-10 Slightly haemolytic 
10-20 Moderately haemolytic 
20-40 Markedly haemolytic 
40 Severely haemolytic 
Table 3.2. Haemolysis results using Blankey and Dinewoodie spectra method. 
Samples 
Haemoglobin 
released 
(g/L) 
Haemolytic 
index (%) Haemolytic grade 
Negative control 0.036 0.026 Non haemolytic 
Positive control 3.6 2.6 Slightly haemolytic 
First column 0.043 0.03 Non haemolytic 
Second column 0.033 0.024 Non haemolytic 
Third column 0.115 0.082 Non haemolytic 
Fourth column 0.238 0.171 Non haemolytic 
Table 3.3. Haemolysis results using Sysmex cell counter. 
Samples 
Haemoglobin 
released 
(g/L) 
Haemolytic 
index (%) Haemolytic grade 
Negative control 1.28 0.92 Non haemolytic 
Positive control 12.8 9.21 Moderately haemolytic 
First column 1.07 0.76 Non haemolytic 
Second column 1.23 0.88 Non haemolytic 
Third column 1.04 0.75 Non haemolytic 
Fourth column 1.29 0.93 Non haemolytic 
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3.4. Coupling of Anti-human Albumin (IgG) Ligand onto 
Monolithic Epoxy PHEMA Cryogel 
Monolithic macroporous cryogels produced from epoxy 
PHEMA were macroporous polymeric materials with 
interconnected pore structure.  
The quantity of IgG (protein content) immobilised on 8% 
w/v epoxy PHEMA was estimated by the standard BCA 
method. The results of proteins and protein based 
immobilisation yields are summarized in Table. 3.4. This 
result shows approximately 91% of IgG protein was 
immobilised on HEMA: AGE cryogels. However, the epoxy 
plain cryogels (cryogels with no surface derivatised with 
either ethylenediamine or glutaraldehyde, but incubated with 
protein) had no protein on the surface of the cryogel.  
Table 3.4. Protein (IgG) contents on monolithic cryogels determined using 
bicinchoninic acid (BCA) method (Mean ± SD n=3). 
Cryogel total monomer 
concentration 
Protein content per 
weight of monolith 
(mg/g-monolith) 
Immobilisation 
yield (%) 
8% w/v HEMA: AGE  290 ± 26.4 91.5 
8% w/v Plain HEMA: AGE  10 ± 1.5 3.2 
3.5. Affinity Binding of Human Albumin to Cryogel with 
Immobilised IgG 
Table 3.5 presents the binding of human serum albumin. 
Prior to affinity binding of the human serum albumin on the 
cryogel–protein surfaces, as a control, the human serum 
albumin was applied to 4 mL epoxy PHEMA cryogel matrix 
(without affinity ligand). The human serum albumin capture 
performed on such control surfaces showed minimum non-
specific binding (<10%). About 82% of human serum 
albumin was retained on the monolithic IgG cryogel matrix.  
Table 3.5. Total protein (anti-human albumin (IgG) plus human serum 
albumin) contents on monolithic cryogels determined using bicinchoninic 
acid (BCA) method (Mean ± SD n=3). 
Cryogel total monomer 
concentration 
Protein content per 
weight of monolith 
(mg/g –monolith) 
Immobilisation 
yield (%) 
8% w/v HEMA: AGE  556 ± 25.8 82 
8% w/v Plain HEMA: AGE  15 ± 1.3 2.2 
4. Discussion 
In this study the haemolytic potential of poly (2-
hydroxyethyl methacrylate) PHEMA cryogels was analysed. 
The degree of haemolysis (Haemolytic Index) was 
determined by calculating the amount of free haemoglobin in 
the blood substrate supernatants after photometric detection 
at 562, 578 and 598 nm. The haemolytic index of the sample 
test was compared with that of the negative and positive 
control. 
The data show that the haemolytic indices of the blood 
substrate supernatants of the negative control and the sample 
test were below 1% and therefore the material is classified as 
non-haemolytic. 
A treatment of the blood substrate with deionised water 
(positive control) lead to a substantial increase in the 
haemolytic index (mean 5.90). According to the converting 
criteria the positive control has to be classified as slightly 
haemolytic. 
 The 100% elution of RBC without haemolysis after 12 
minutes could indicate that the 8% PHEMA cryogel column 
has interconnected pores large enough for the passage of cells 
as big as 7-10 µm without any hindrances or entrapment.  
The large pore size in the cryogel, in combination with the 
highly interconnected pore morphology and hydrophilic 
nature of pore walls formed from a cryogel, allow molecules 
and larger blood constituents such as cells of nano to micro 
meter size to pass unretained through the monolithic cryogel 
column in the absence of ionic or specific interactions 
between the ligands coupled to the cryogel. Steric hindrance 
between immobilised ligand (antibody IgG) and large target 
molecules can occur during interaction with immobilised 
protein [33].  
To overcome this problem, the IgG was coupled to the 
epoxy-containing macroporous cryogel matrix through a 
spacer arm. The two-step derivatisation includes reaction 
with ethylenediamine, followed by the reaction with 
glutaraldehyde giving a spacer arm of seven carbon atoms. 
Further improvement in the binding efficiency could be 
expected when using even longer extension arms, but this 
may also increase the non-specific binding in some cases. 
The results show at least 90% of the amount of IgG used was 
immobilised onto the cryogel surface  
The absence of immobilisation on epoxy plain cryogels 
(cryogels with no surface derivatised with either 
ethylenediamine or glutaraldehyde, but incubated with 
protein) explains that protein cannot be adsorbed or bound 
easily onto the cryogel matrix because the cryogel possesses 
hydrophilic features with low non-specific adsorption of 
protein and also adsorption is difficult without a spacer arm. 
Non-specific absorption of proteins to the surface occurs 
naturally, whenever protein has contact with any surface. 
However, bio-specific affinity reaction occurs with the use of 
biological compounds such as immunoglobulin-binding 
proteins, enzymes, lectins and carbohydrates as ligands. The 
analyte is captured in a highly selective manner via 
molecular recognition by the ligand present on the column. 
The results could suggest that direct immobilisation of 
antibodies on the cryogel material and applying for affinity 
captures a lower binding when compared with about 95% 
specific cell binding on protein A monolithic cryogel matrix 
as reported in [34] and about 94% of specific B-cells on 
protein A column was reported in [24]. This may be because 
of the poor orientation and also some inactivation of the 
antibody molecules when coupled directly to the matrix. For 
better orientation of the immobilised antibody molecules, one 
of the most common methods utilized is the immobilisation 
of antibodies at Fc region through the use of protein A [35].  
Cryogel is a highly porous polymeric material, which 
possesses large pore size and hence results in a small area 
(per unit of column volume) available for ligand coupling 
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and hence in low binding capacity for protein binding [36], 
as compared with traditional packed-bed adsorbents. 
However, low ligand density seems to be beneficial for 
chromatographic separation of cells having multiple 
interactions with the surface. High ligand densities result in 
multipoint cell-matrix interactions and hence problems with 
the recovery of bound cells [37]. The potential of polymeric 
cryogels in bioseparation has been discussed earlier in a 
review [38, 39]. This present work demonstrates that 
cryogels have promising potential, as separation media when 
dealing with macromolecules, thus might be a suitable filter 
matrix in extracorporeal apheresis device. 
5. Conclusions 
It has been proved in this study that under the indicated 
conditions poly (2-hydroxyethyl methacrylate) PHEMA 
cryogels did not contain any leachable substances with 
haemolytic activity. The haemocompatibility finding shows 
approximately 100% of Red blood cells was eluted after 
passage through the column, with no haemolysis observed in 
the eluent. The results from Sysmex cell counter correlate 
with data from Blankey and Dinewoodie spectra method, 
therefore PHEMA cryogel could be classified as non-
haemolytic. Immobilisation of anti-human albumin (IgG) and 
affinity binding of human serum albumin to the IgG 
immobilised matrix demonstrate the bio-affinity potential of 
antibody used as ligands for protein purification. Thus, 
monolithic cryogels have promising potential as a matrix for 
blood purification and can be a suitable matrix for 
extracorporeal apheresis medical devices. 
Acknowledgement 
The authors are grateful to Prof Dieter Falkenhagen, Dr 
Viktoria Weber and Dr Anita Schildberger of Department 
for Clinical Medicine and Biotechnology, Centre for 
Biomedical Technology Krems Donau University (Austria) 
for their help with haemolytic potential test. Prof Bo 
Mattiasson and Dr Harald Kirsebom of Department of 
Biotechnology, Centre for Chemistry and Chemical 
Engineering, Lund University (Sweden) for guidance with 
functionalisation of the matrix. 
This work was financially supported by European 
Commission Marie Curie Actions FP7 IAPP MONACO 
EXTRA project (218242), Erasmus grant and University of 
Brighton PhD studentship. 
 
References 
[1] Ratner, B.D., et al., Biomaterials Science - An Introduction to 
Materials in Medicine, ed. n. Edition. 2004: Elsevier. 
[2] Ratner, B.D., et al., Introduction - Biomaterials Science: An 
Evolving, Multidisciplinary Endeavor, in Biomaterials 
Science (Third Edition), B.D.R.S.H.J.S.E. Lemons, Editor. 
2013, Academic Press. p. xxv-xxxix. 
[3] Ueki, Y., et al., Evaluation of filtration leucocytapheresis for 
use in the treatment of patients with rheumatoid arthritis. 
Rheumatology, 2000. 39(2): p. 165-171. 
[4] Hidaka, T., et al., Filtration leukocytapheresis therapy in 
rheumatoid arthritis: A randomized, double-blind, placebo-
controlled trial. Arthritis & Rheumatism, 1999. 42(3): p. 431-
437. 
[5] Morihiro, O., et al., Granulocytapheresis in the treatment of 
patients with rheumatoid arthritis. Journal of Artificial Organs, 
1997. 21(9): p. 989-994. 
[6] Sawada, K., et al., Leukocytapheresis therapy, performed with 
leukocyte removal filter, for inflammatory bowel disease. 
Journal of Gastroenterology, 1995. 30(3): p. 322-329. 
[7] Rembacken, B.J., et al., Granulocyte apheresis in inflammatory 
bowel disease: Possible mechanisms of effect. Therapeutic 
Apheresis and Dialysis, 1998. 2(2): p. 93-96. 
[8] Shimoyama, T., et al., Safety and efficacy of granulocyte and 
monocyte adsorption apheresis in patients with active 
ulcerative colitis: A multicenter study. Journal of Clinical 
Apheresis, 2001. 16(1): p. 1-9. 
[9] Bosch, T., et al., Direct adsorption of low-density lipoprotein 
and lipoprotein(a) from whole blood: Results of the first 
clinical long-term multicenter study using DALI apheresis. 
Journal of Clinical Apheresis, 2002. 17(4): p. 161-169. 
[10] Bosch, T. and T. Wendler, Efficacy and safety of DALI-LDL-
apheresis in two patients treated with the angiotensin II-
receptor 1 antagonist losartan. Therapeutic Apheresis and 
Dialysis, 2004. 8(4): p. 269-274. 
[11] Shibata, H., T. Kuriyama, and N. Yamawaki, Cellsorba. 
Therapeutic Apheresis and Dialysis, 2003. 7(1): p. 44-47. 
[12] Saniabadi, A.R., et al., Adacolumn, an adsorptive carrier based 
granulocyte and monocyte apheresis device for the treatment of 
inflammatory and refractory diseases associated with 
leukocytes. Therapeutic Apheresis and Dialysis, 2003. 7(1): p. 
48-59. 
[13] Agishi, T., Birth of the concept and the development of 
extracorporeal immunomodulation. Therapeutic Apheresis, 
2002. 6(4): p. 312-316. 
[14] Archontakis, S., P. Alison, and B. Mahmoud, Low-density 
lipoprotein-apheresis: an update. The British Journal of 
Cardiology, 2008. 15(2): p. 83-85. 
[15] Bosch, T., et al., DALI apheresis in hyperlipidemic patients: 
biocompatibility, efficacy, and selectivity of direct adsorption 
of lipoproteins from whole blood. Artificial Organs, 2000. 
24(2): p. 81-90. 
[16] Tetala, K.K.R. and T.A. van Beek, Bioaffinity chromatography 
on monolithic supports. Journal of Separation Science, 2010. 
33(3): p. 422-438. 
[17] Svec, F. and J.M.J. Frechet, New designs of macroporous 
polymers and supports: from separation to biocatalysis. 
Science, 1996. 273(5272): p. 205-211. 
[18] Akande Wuraola, et al., Poly (2-Hydroxyethyl Methacrylate) 
Macroporous Cryogel for Extracorporeal Medical Devices. 
International Journal of Biomedical Materials Research, 2015. 
3(4): p. 46-55. 
63 Wuraola Akande et al.:  Affinity Binding Macroporous Monolithic Cryogel as a Matrix for Extracorporeal 
Apheresis Medical Devices 
[19] Dainiak, M.B., I.Y. Galaev, and B. Mattiasson, Affinity 
cryogel monoliths for screening for optimal separation 
conditions and chromatographic separation of cells. Journal of 
Chromatography A, 2006. 1123(2): p. 145-150. 
[20] Gun'ko, V.M., I.N. Savina, and S.V. Mikhalovsky, Cryogels: 
morphological, structural and adsorption characterisation. Adv 
Colloid Interface Sci, 2013. 187-188: p. 1-46. 
[21] Dainiak, M.B., et al., Detachment of affinity-captured 
bioparticles by elastic deformation of a macroporous 
hydrogel. Proceedings of the National Academy of Sciences, 
2006. 103(4): p. 849-854. 
[22] Savina, I.N., et al., Porous structure and water state in cross-
linked polymer and protein cryo-hydrogels. Soft Matter, 2011. 
7(9): p. 4276-4283. 
[23] Onodera, H., et al., Development of a device for selective 
removal of CD4+ T cells. Therapeutic Apheresis and Dialysis, 
2003. 7(3): p. 329-333. 
[24] Kumar, A., et al., Affinity fractionation of lymphocytes using 
a monolithic cryogel. Journal of Immunological Methods, 
2003. 283(1-2): p. 185-194. 
[25] Ingavle, G.C., et al., Affinity binding of antibodies to 
supermacroporous cryogel adsorbents with immobilized 
protein A for removal of anthrax toxin protective antigen. 
Biomaterials, 2015. 50: p. 140-53. 
[26] Kempe, D.S., et al., Stimulation of erythrocyte 
phosphatidylserine exposure by lead ions. American Journal 
of Physiology - Cell Physiology, 2005. 288(2): p. C396-C402. 
[27] Streller, U., et al., Design and evaluation of novel blood 
incubation systems for in vitro hemocompatibility assessment 
of planar solid surfaces. Journal of Biomedical Materials 
Research Part B: Applied Biomaterials, 2003. 66B(1): p. 379-
390. 
[28] Henkelman, S., et al., Standardization of incubation conditions 
for hemolysis testing of biomaterials. Materials Science and 
Engineering: C, 2009. 29(5): p. 1650-1654. 
[29] Dillingham, E.O., et al., Biological evaluation of polymers I. 
Poly(methyl methacylate). Journal of Biomedical Materials 
Research, 1975. 9(6): p. 569-596. 
[30] Blakney, G. B, and A. Dinwoodie, J., A spectrophotometric 
scanning technique for the rapid determination of plasma 
hemoglobin. Journal of Clinical Biochemistry, 1975. 8(2): p. 
96-102. 
[31] Smith, P.K., et al., Measurement of protein using 
bicinchoninic acid. Analytical Biochemistry, 1985. 150(1): p. 
76-85. 
[32] Kay, L.A., Essentials of haemostasis and thrombosis, in 
Essentials of haemostasis and thrombosis. 1988, Churchill 
Livingstone, Edinburgh. p. 290. 
[33] Luo, Q., et al., High-performance affinity chromatography 
with immobilization of protein A and L-histidine on molded 
monolith. Biotechnology and Bioengineering, 2002. 80(5): p. 
481-489. 
[34] Kumar, A., et al., Affinity binding of cells to cryogel 
adsorbents with immobilized specific ligands: effect of ligand 
coupling and matrix architecture. Journal of Molecular 
Recognition, 2005. 18(1): p. 84-93. 
[35] Anderson, G.P., et al., Effectiveness of protein A for antibody 
immobilization for a fiber optic biosensor. Biosensors and 
Bioelectronics, 1997. 12(4): p. 329-336. 
[36] Arvidsson, P., et al., Direct chromatographic capture of 
enzyme from crude homogenate using immobilized metal 
affinity chromatography on a continuous supermacroporous 
adsorbent. Journal of Chromatography A, 2003. 986(2): p. 
275-90. 
[37] Ujam, L.B., et al., Isolation of monocytes from human 
peripheral blood using immuno-affinity expanded-bed 
adsorption. Biotechnology and Bioengineering, 2003. 83(5): 
p. 554-566. 
[38] Lozinsky, V., et al., The potential of polymeric cryogels in 
bioseparation. Bioseparation, 2001. 10(4): p. 163-188. 
[39] Hajizadeh, S., and B. Mattiasson, Cryogels with Affinity 
Ligands as Tools in Protein Purification, in Affinity 
Chromatography, S. Reichelt, Editor. 2015, Springer New 
York. p. 183-200.   
